Sarah Boyce
CIK 1629383 · President and CEO · last filed 2026-09-22
Sarah Boyce is a President and CEO who has filed 68 SEC Form 4 insider transactions across 9 companies since 2015. The most recent filing shows the insider had shares withheld for taxes covering $1.1M of RNA on Sep 22, 2026. Across all open-market trades the lifetime net is −$33.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.5M across reported positions. 11 SEC filings were submitted jointly with IONIS PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RNA | President and CEO | 138,668 | $8.05 | $1.12M | -$33.09M | 28 | 2026-09-22 |
| CTNM | Director | — | $8.14 | — | $0 | 3 | 2026-06-26 |
| Avidity Biosciences, Inc. (RNAM) Delisted | President and CEO | 0 | — | — | $0 | 1 | 2026-02-27 |
| OABIW | Director | 104,381 | $0.39 | $40.4K | $101.4K | 5 | 2024-06-21 |
| LGND | Director | 2,892 | $308.30 | $891.6K | $0 | 5 | 2022-11-03 |
| Bruker Cellular Analysis, Inc. (BLI) Delisted | Director | 1,400 | $1.20 | $1.7K | -$611.3K | 2 | 2021-05-18 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | President | 19,888 | — | — | -$42.8K | 4 | 2019-07-17 |
| IONS | Chief Business Officer | 11,127 | $43.42 | $483.1K | -$212.8K | 8 | 2018-01-17 |
| IONIS PHARMACEUTICALS INC (ISIS) Delisted | Chief Business Officer | — | — | — | $0 | 2 | 2015-01-20 |
Recent Filings
68 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-22 | RNA | Tax (F) | −126,418 | -$1.13M | EDGAR |
| 2026-06-26 | CTNM | Grant (A) | — | $0 | EDGAR |
| 2026-03-02 | — | Grant (A) | — | $0 | |
| 2026-02-27 | Avidity Biosciences, Inc. (RNAM) Delisted | Disp (D) | −474,861 | $0 | EDGAR |
| 2026-01-23 | RNA | Sell (S) | −14,387 | -$1.04M | EDGAR |
| 2026-01-09 | RNA | Sell (S) | −8,576 | -$619.4K | EDGAR |
| 2025-12-19 | RNA | Mixed | −13,901 | -$1.13M | EDGAR |
| 2025-09-05 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −50,000 | -$2.42M | EDGAR |
| 2025-09-05 | RNA | Mixed | — | -$2.44M | EDGAR |
| 2025-08-29 | RNA | Mixed | — | -$1.20M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.